ArticleThe Journal of rheumatology2008
Trends in drug prescribing for osteoporosis after hip fracture, 1995-2004.
Article in The Journal of rheumatology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 68 citations in OpenAlex.
- Effect of bisphosphonate initiation at week 2 versus week 12 on short-term functional recovery after femoral neck fracture: a randomized controlled trial.Archives of osteoporosis · 2017Trial
- The PAADRN study: a design for a randomized controlled practical clinical trial to improve bone health.Contemporary clinical trials · 2013Trial
- A novel case-finding strategy based on artificial intelligence for the systematic identification and management of individuals with osteoporosis or at varying risk of fragility fracture.Archives of osteoporosis · 2024Article
- Treatment rates and healthcare costs of patients with fragility fracture by site of care: a real-world data analysis.Archives of osteoporosis · 2023Article
- Feasibility, acceptability, and preliminary effects of PATH FOR timely transfer of geriatric HIP fracture patients from hospital to rehabilitation to home (PATH4HIP): a protocol for a mixed method study.Pilot and feasibility studies · 2022Article
- Effect of Dosing Interval on Compliance of Osteoporosis Patients on Bisphosphonate Therapy: Observational Study Using Nationwide Insurance Claims Data.Journal of clinical medicine · 2021Article
- Osteoporosis treatment rates after hip fracture 2011-2019 in Hawaii: Undertreatment of men after hip fractures.Osteoporosis and sarcopenia · 2021Article
- Global epidemiology of hip fractures: a study protocol using a common analytical platform among multiple countries.BMJ open · 2021Article
- Which patients are at risk for not receiving anti-osteoporosis treatment following hip fracture?: An ACS NSQIP analysis.Journal of clinical orthopaedics and trauma · 2021Article
- Clinical characteristics and outcomes of patients presenting with hip fractures at a tertiary care hospital in Pakistan.Archives of osteoporosis · 2021Article
- Trends in the Diagnosis of Osteoporosis in Patients with Distal Radius Fractures Based on a National Claims Database.Journal of bone metabolism · 2019Article
- Use of anti-osteoporosis medication dispensing by patients with hip fracture: could we do better?Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019Article
- Gender differences in anti-osteoporosis drug treatment after osteoporotic fractures.Journal of bone and mineral metabolism · 2019Article
- Minodronate for the treatment of osteoporosis.Therapeutics and clinical risk management · 2018Review
- Factors Affecting Bone Mineral Density Measurement after Fracture in South Korea.Journal of bone metabolism · 2017Article
- Diagnosis and Treatment of Osteoporosis Before and After Fracture: A Side-by-Side Analysis of Commercially Insured and Medicare Advantage Osteoporosis Patients.Journal of managed care & specialty pharmacy · 2017Article
- Trends in post osteoporotic hip fracture care from 2010 to 2014 in a private hospital in Malaysia.Osteoporosis and sarcopenia · 2017Article
- Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000-2010.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2015Article
- The risk of major and any (non-hip) fragility fracture after hip fracture in the United Kingdom: 2000-2010.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2014Article
- Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2014Observational
Corrections and comments
- Commented on by
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo examine trends in osteoporosis drug prescribing after hip fracture from 1995 to 2004.
methodsWe conducted a population-based study of enrollees in the Pennsylvania Pharmaceutical Assistance Contract for the Elderly. Hip fractures were identified using Medicare hospital claims between January 1, 1995, and June 30, 2004. Osteoporosis treatment comprised oral bisphosphonates, calcitonin, hormone therapy, raloxifene, and/or teriparatide. Kaplan-Meier methods were used to estimate the probability of treatment within 6 months of fracture, censoring patients on their date of death or 6 months postfracture.
resultsTreatment within 6 months after hip fracture improved from 7% in 1995 to 31% in 2002, and then remained stable through 2004. Similar patterns were observed among new users, with treatment increasing from 4% in 1995 to 17% in 2002, with no subsequent increase through 2004. Bisphosphonates led other treatments in the frequency of prescribing, except during 1997-99, when calcitonin was the most common. Among women, hormone therapy prescribing decreased from 22% of those treated in 1995 to 4% in 2004, and raloxifene prescribing remained relatively constant (4%-10%) since its introduction (p for trend = 0.15). Of patients treated before and after hip fracture, 18% changed therapy postfracture. Significantly more patients changed therapy following fracture if a different physician prescribed treatment (26%) compared to those treated by the same physician pre- and postfracture (13%; p < 0.0001).
conclusionPrescribing practices changed substantially over the 10 years of study. The proportion of hip fracture patients treated with osteoporosis drugs has increased, but remains low, with fewer than one-third receiving pharmacotherapy.
Indexed as
Identifiers
18061977PMC3256248W1943094800What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.